Clene Inc. reports results for the quarter ended December 31 - Earnings Summary

• Clene Inc. CLNN.OQ reported a quarterly adjusted loss of $1.86​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $-1.20. The mean expectation of six analysts for the quarter was for a loss of 95 cents per share. Wall Street expected results to range from $-1.31 to -42 cents per share.

• Revenue fell 46.5% to $91.00 thousand from a year ago; analysts expected $130.00 thousand.

• Clene Inc.'s reported EPS for the quarter was a loss of $1.67​.

• The company reported a quarterly loss of $13.55 million.

• Clene Inc. shares had fallen by 22.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Clene Inc. is $30.50

This summary was machine generated from LSEG data March 24 at 03:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)